Chemsex in HIV pre-exposure prophylaxis users: Assessment of mood disorders and addictive behavior.


Journal

Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411

Informations de publication

Date de publication:
Jun 2023
Historique:
revised: 03 10 2022
received: 11 04 2022
accepted: 17 11 2022
medline: 12 5 2023
pubmed: 21 11 2022
entrez: 20 11 2022
Statut: ppublish

Résumé

The assessment of mood disorders and addiction linked to the practice of chemsex is of interest given the psychoactive substances used. The aim of this study was to assess risky sexual and addictive behavior to chemsex and related anxiety/depression symptoms in individuals receiving HIV pre-exposure prophylaxis (PrEP). In this cross-sectional study, all adults presenting for PrEP renewal at French sexual health centers were enrolled from January 2018 to March 2019. Participants completed a questionnaire on chemsex (i.e., the use of psychoactive substances before/during sex), including adapted Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) to chemsex addiction (questions of ASSIST were modified to focus on chemsex). Anxiety/depression was assessed with the Hospital Anxiety and Depression Scale. In the last 3 months before enrollment, 39.8% (94/236) of participants reported chemsex. The main psychoactive substances consumed during chemsex were cathinones (74.6%), gamma-hydroxybutyrate (66.3%), and other psychostimulants (60%). The median score of the chemsex-focused ASSIST was 8 [IQR

Identifiants

pubmed: 36403123
doi: 10.1111/fcp.12854
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

639-649

Informations de copyright

© 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.

Références

Edmundson C, Heinsbroek E, Glass R, et al. Sexualised drug use in the United Kingdom (UK): a review of the literature. Int J Drug Policy. 2018;55:131-148. doi:10.1016/j.drugpo.2018.02.002
Fisher DG, Reynolds GL, Ware MR, Napper LE. Methamphetamine and Viagra use: relationship to sexual risk behaviors. Arch Sex Behav. 2011;40(2):273-279. doi:10.1007/s10508-009-9495-5
Melendez-Torres GJ, Bourne A, Hickson F, Reid D, Weatherburn P. Correlates and subgroups of injecting drug use in UK gay and bisexual men: findings from the 2014 gay men's sex survey. Drug Alcohol Depend. 2018;187:292-295. doi:10.1016/j.drugalcdep.2018.03.014
Benotsch EG, Lance SP, Nettles CD, Koester S. Attitudes toward methamphetamine use and HIV risk behavior in men who have sex with men. Am J Addict. 2012;21:S35-S42. doi:10.1111/j.1521-0391.2012.00294.x
Bui H, Zablotska-Manos I, Hammoud M, et al. Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: results from the FLUX study. Int J Drug Policy. 2018;55:222-230. doi:10.1016/j.drugpo.2018.01.018
Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviors among men who have sex with men: a systematic review of the literature. Int J Drug Policy. 2019;63:74-89. doi:10.1016/j.drugpo.2018.11.014
Donnadieu-Rigole H, Peyrière H, Benyamina A, Karila L. Complications related to sexualized drug use: what can we learn from literature? Front Neurosci. 2020;14:548704. doi:10.3389/fnins.2020.548704
Dolengevich-Segal H, Gonzalez-Baeza A, Valencia J, et al. Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): data from the U-SEX GESIDA 9416 study. PLoS One. 2019;14(12):e0220272. doi:10.1371/journal.pone.0220272. eCollection 2019
Lafortune D, Blais M, Miller G, Dion L, Lalonde F, Dargis L. Psychological and interpersonal factors associated with sexualized drug use among men who have sex with men: a mixed-Methods systematic review. Arch Sex Behav. 2021;50(2):427-460. doi:10.1007/s10508-020-01741-8
Íncera-Fernández D, Gámez-Guadix M, Moreno-Guillén S. Mental health symptoms associated with sexualized drug use (chemsex) among men who have sex with men: a systematic review. Int J Environ Res Public Health. 2021;18(24):13299. doi:10.3390/ijerph182413299
Batisse A, Eiden C, Deheul S, Monzon E, Djezzar S, Peyrière H. Chemsex practice in France: An update in addictovigilance data. Fundam Clin Pharmacol. 2021;36(2):397-404. doi:10.1111/fcp.12725
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599. doi:10.1056/NEJMoa1011205
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015. https://apps.who.int/iris/bitstream/handle/10665/186275/9789241509565eng.pdf?sequence=1
Roux P, Fressard L, Suzan-Monti M, et al. Is on-demand HIV pre-exposure prophylaxis a suitable tool for men who have sex with men who practice chemsex? Results from a substudy of the ANRS-IPERGAY trial. J Acquir Immune Defic Syndr. 2018;79(2):e69-e75. doi:10.1097/QAI.0000000000001781
Hegazi A, Lee MJ, Whittaker W, et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J STD AIDS. 2017;28(4):362-366. doi:10.1177/0956462416651229
Pakianathan M, Whittaker W, Lee MJ, et al. Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. HIV Med. 2018;19(7):485-490. doi:10.1111/hiv.12629
Hanum N, Cambiano V, Sewell J, et al. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health. 2020;5(9):e501-e511. doi:10.1016/S2468-2667(20)30186-9
Humeniuk R, Ali R, Babor T, et al. A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction. 2012;107(5):957-966. doi:10.1111/j.1360-0443.2011.03740.x
Humeniuk R, Ali R, Babor TF, et al. Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction. 2008;103(6):1039-1047. doi:10.1111/j.1360-0443.2007.02114.x
Dawson Rose C, Cuca YP, Kamitani E, et al. Using interactive web-based screening, brief intervention and referral to treatment in an urban, safety-net HIV clinic. AIDS Behav. 2015;19(Suppl 2(0 2)):186-193.
Jacquet JM, Donnadieu-Rigole H, Peries M, et al. MesConsos study group name. Implementing screening, brief intervention and referral to treatment in a French cohort of people living with HIV: a pilot study. HIV Med. 2019;20(4):286-290. doi:10.1111/hiv.12709
http://www.who.int/substance_abuse/terminology/who_ladt/fr/
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x
Glynn RW, Byrne N, O'Dea S, et al. Chemsex, risk behaviors and sexually transmitted infections among men who have sex with men in Dublin, Ireland. Int J Drug Policy. 2018;52:9-15. doi:10.1016/j.drugpo.2017.10.008
Sewell J, Miltz A, Lampe FC, et al. Poly drug use, chemsex drug use, and associations with sexual risk behavior in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33-43. doi:10.1016/j.drugpo.2017.01.001
Drückler S, Van Rooijen MS, de Vries HJC. Chemsex among men who have sex with men: a sexualized drug use survey among clients of the sexually transmitted infection outpatient clinic and users of a gay dating app in Amsterdam, the Netherlands. Sex Transm Dis. 2018;45(5):325-331. doi:10.1097/OLQ.0000000000000753
Pufall EL, Kall M, Shahmanesh M, et al. Sexualized drug use (‘chemsex’) and high-risk sexual behaviours in HIV-positive men who have sex with men study group. HIV Med. 2018;19(4):261-270. doi:10.1111/hiv.12574
Velter A, Sauvage C, Saboni L, et al. Estimation de la prévalence du VIH chez les hommes ayant des relations sexuelles avec des hommes fréquentant les lieux de convivialité gay de cinq villes françaises - PREVAGAY 2015. Bull Epidémiol Hebd 2017; 18: 347-354. http://invs.santepubliquefrance.fr/beh/2017/18/2017_18_1.html
O'Halloran C, Rice B, White E, et al. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants. Int J Drug Policy. 2019;74:246-254. doi:10.1016/j.drugpo.2019.10.007
Traeger MW, Cornelisse VJ, Asselin J, et al. PrEPX study team association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. Jama. 2019;321(14):1380-1390. doi:10.1001/jama.2019.2947
Tomkins A, Ahmad S, Cannon L, et al. Prevalence of recreational drug use reported by men who have sex with men attending sexual health clinics in Manchester, UK. Int J STD AIDS. 2018;29:350-356.
Bourne A. The chemsex study: Drug use in sexual settings among gay and bisexual men in Lambeth. Sigma Research: Southwark & Lewisham; 2014.
Tomkins A, George R, Kliner M. Sexualised drug taking among men who have sex with men: a systematic review. Perspect Public Health. 2019;139(1):23-33. doi:10.1177/1757913918778872
Karila L, Megarbane B, Cottencin O, Lejoyeux M. Synthetic cathinones: a new public health problem. Curr Neuropharmacol. 2015;13(1):12-20. doi:10.2174/1570159X13666141210224137
Wojcieszak J, Andrzejczak D, Szymańska B, Zawilska JB. Induction of immediate early genes expression in the mouse striatum following acute administration of synthetic cathinones. Pharmacol Rep. 2019;71(6):977-982. doi:10.1016/j.pharep.2019.05.011
Prestage G, Hammoud M, Jin F, Degenhardt L, Bourne A, Maher L. Mental health, drug use and sexual risk behavior among gay and bisexual men. Int J Drug Policy. 2018;55:169-179. doi:10.1016/j.drugpo.2018.01.020
Miltz A, Lampe F, McCormack S, et al. Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis. BMJ Open. 2019;9(12):e031085. doi:10.1136/bmjopen-2019-031085
Trouiller P, Velter A, Saboni L, et al. Injecting drug use during sex (known as "slamming") among men who have sex with men: results from a time-location sampling survey conducted in five cities, France. Int J Drug Policy. 2020;79:102703. doi:10.1016/j.drugpo.2020.102703
Sewell J, Cambiano V, Speakman A, et al. Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study. Int J Drug Policy. 2019;68:54-61. doi:10.1016/j.drugpo.2019.03.021

Auteurs

Hélène Peyriere (H)

INSERM U1175/IRD UMI 233, Montpellier University, Montpellier, France.
Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.

Jean-Marc Jacquet (JM)

Department of Addictology, Nimes University Hospital, Nimes, France.

Marianne Peries (M)

Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.

Vincent Tribout (V)

Sexual Transmitted Infections Center, Montpellier University, Montpellier, France.

Béatrice Broche (B)

Sexual Transmitted Infections Center, Nimes, France.

Jean-Marc Mauboussin (JM)

Infectious Diseases Department, Nimes University Hospital, Nimes, France.

Alain Makinson (A)

INSERM U1175/IRD UMI 233, Montpellier University, Montpellier, France.
Infectious Diseases Department, Montpellier University Hospital, Montpellier, France.

Cyril Perrollaz (C)

Sexual Transmitted Infections Center, Montpellier University, Montpellier, France.

Milagros Ferreyra (M)

Sexual Transmitted Infections Center, Perpignan, France.

Isabelle Rouanet (I)

Infectious Diseases Department, Nimes University Hospital, Nimes, France.

Ana Montoya-Ferrer (A)

Infectious Diseases Department, Montpellier University Hospital, Montpellier, France.

Said El-Majjaoui (S)

Sexual Transmitted Infections Center, Nimes, France.

Florence Corriol-Bonifas (F)

Infectious Diseases Department, Alès Hospital, Alès, France.

Thibaut Fraisse (T)

Infectious Diseases Department, Alès Hospital, Alès, France.

Fanny Grau (F)

Sexual Transmitted Infections Center, Nimes, France.

Didier Laureillard (D)

Infectious Diseases Department, Nimes University Hospital, Nimes, France.

Nicolas Nagot (N)

Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.

Jacques Reynes (J)

INSERM U1175/IRD UMI 233, Montpellier University, Montpellier, France.
Infectious Diseases Department, Montpellier University Hospital, Montpellier, France.

Hélène Donnadieu-Rigole (H)

Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU Montpellier, Montpellier, France.
Department of Addictology, Montpellier University Hospital, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH